Eclipse extension.
Completed
- Conditions
- COPD, biological markers
- Registration Number
- NL-OMON29112
- Lead Sponsor
- Centrum:CIRO+, expertisecentrum voor chronisch orgaanfalen.Plaats:HornHoofdonderzoeker:Prof. Dr. E.F.M. Wouters
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
A COPD subject will be eligible for inclusion in this study only if all of the following criteria apply:
1. Male or female subjects, aged 40-75 years inclusive;
Exclusion Criteria
A COPD subject will not be eligible for inclusion in this study only if all of the following criteria apply:
1. Known respiratory disorders, or disorders identified at screening/visit 1 (including identification on the first CT-scan), other than COPD (e.g.: lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis);
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary study parameters of ECLIPSE extension with an additional three years follow-up are:<br /><br>1. The 6 years natural history of the following phenotypes of COPD: GOLD stage II till IV; cachexia; respiratory failure; frequent exacerbators; and predominantly emphysema and predominantly airway disease;<br /><br>2. The relationship between the progressions of the above phenotypes;<br /><br>3. How the baseline data of ECLIPSE predicts the above phenotypes;<br /><br>4. How the progression of the above phenotypes relates to all-cause mortality and mortality of COPD.
- Secondary Outcome Measures
Name Time Method